Taken together, these data suggest that the pro-apoptotic synergy between Maritoclax and ABT-737 is, at least in part, due to the degradation of Mcl-1 induced by Maritoclax and simultaneous inhibition of Mcl-1 and Bcl-2 may be an effective strategy for melanoma therapy. The gene discussed is BCL2; the disease is melanoma.